Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)

NCT ID: NCT02393417

Last Updated: 2019-06-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 243 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-31
• Study Completion Date: 2018-03-31

Brief Summary

This is a placebo-controlled, double-blind (subject, Investigator, and site staff with the exception of unblinded dedicated staff to handle study medication), phase 2a study with 3 dose cohorts, randomized (concealed) to CANDIN or placebo (3:1). Main study will be up to 20 weeks (10 doses administered every other week) or until a subject has complete resolution of all injectable common warts. Subjects who cannot tolerate dosing every 2 weeks due to a local tolerance issue may be injected at 3-week intervals for up to 10 doses, increasing the length of the study to 29 weeks. Subjects will be followed for 4 months after final injection(s) for evidence of new or reoccurring warts and for safety evaluation.

Conditions

Warts

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Cohort 1

0.3 mL of CANDIN administered intralesionally in the largest common wart

Group Type: EXPERIMENTAL

CANDIN

Intervention Type: BIOLOGICAL

Candida albicans Skin Test Antigen for Cellular Hypersensitivity

Cohort 2

0.5 mL of CANDIN administered intralesionally in the largest common wart

Group Type: EXPERIMENTAL

CANDIN

Intervention Type: BIOLOGICAL

Candida albicans Skin Test Antigen for Cellular Hypersensitivity

Cohort 3

0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)

Group Type: EXPERIMENTAL

CANDIN

Intervention Type: BIOLOGICAL

Candida albicans Skin Test Antigen for Cellular Hypersensitivity

Pooled Placebo

0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

0.9% Sodium Chloride Injection USP (non-preserved)

Interventions

CANDIN

Candida albicans Skin Test Antigen for Cellular Hypersensitivity

Intervention Type: BIOLOGICAL

Placebo

0.9% Sodium Chloride Injection USP (non-preserved)

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Men or women between the ages of 18 and 65 years inclusively at time of consent

2. Subjects presenting with 3 to 20 injectable common warts (verruca vulgaris) for at least 12 weeks at the time of the Baseline Visit

3. Subject's common warts for injection must measure between 3 and 20 mm at Baseline Visit and be located on hands, feet (excluding soles), limbs, and/or trunk. Flat, plantar, facial, periungual, genital warts or warts in region of pre-existing inflammatory condition are excluded from injection

4. Subjects enrolled into Cohort 3 must have common warts for injection in at least 2 different anatomical regions defined as: left arm, right arm, left hand, right hand, left leg, right leg, left foot (excluding sole), right foot (excluding sole) and torso

5. Subject, male or female is willing to use effective contraceptive method for at least 30 days before the Baseline Visit and at least 30 days after the last study drug administration unless not of childbearing potential as defined as post-menopausal for at least 2 years (females) or surgically sterile (tubal ligation, oophorectomy, or hysterectomy for females, and vasectomy for males). The only contraceptive use exceptions would be individuals in exclusive same sex partnerships and individuals who agree to remain non-sexually active for the duration of the study. Acceptable contraceptive methods for subjects include:

• Barrier methods, such as condom, sponge or diaphragm, combined with spermicide in foam, gel or cream;
• Hormonal contraception (oral, intramuscular, implant or transdermal which includes Depo-Provera, Evra and Nuvaring);
• Intrauterine device (IUD)

6. Mentally and legally capable of giving informed consent prior to any study related procedures

Exclusion Criteria

1. Presence of systemic or localized diseases, conditions, or medications that could interfere with assessment of safety and efficacy or that compromise immune function including psoriasis

2. Subject has been diagnosed with diabetes mellitus

3. Subject has a history of keloid formation

4. Injectable common wart(s) located in areas with existing dermatologic conditions (such as psoriasis) or with an underlying inflammatory conditions (such as arthritic joints), or tattoos or implants/piercing/hardware or marking that may conceal responses or reactions are excluded from injection

5. Existing/planned pregnancy, childbirth in the past six months prior to the Baseline Visit, or breast feeding, or plan on donating eggs or sperm during the study and in the month following the last injection

6. Treatment of warts with liquid nitrogen, carbon dioxide, electrodessication, laser, surgery, simple occlusion (e.g. duct tape) salicylic or related acids, OTC treatments, cantharidin, or other treatments within 4 weeks of the Baseline Visit

7. Treatment with immunotherapy (DPCP, DNCB or other), imiquimod, 5-fluorouracil, bleomycin, podophyllin or any other wart immunotherapy or treatment designed to stimulate immune response (except for treatments already listed in exclusion criterion 6) within 12 weeks of the Baseline Visit

8. Recalcitrant warts defined as those not successfully treated by 5 or more treatments (excluding OTC treatments)

9. Abnormal (low < 5 mm or high >25 mm) baseline result to the Delayed Type Hypersensitivity (DTH) test

10. Subject has a condition or treatment resulting in being immunocompromised

11. Systemic treatment (such as oral or injected) with cimetidine, zinc supplements at a dose higher than 20 mg of elemental zinc daily or an immunosuppressive drug (such as: azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab, etanercept, systemic steroids, etc.) within 12 weeks of the Baseline Visit

12. Subject has used any investigational agent within 30 days prior to the Baseline Visit or within 5 half-lives of that investigational agent prior to the Baseline Visit (whichever is longer)

13. Previous treatment of warts with any type of intralesional injection with candida extract (including CANDIN)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nielsen BioSciences, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Thomas Carpenter, DVM, PhD

Role: STUDY_DIRECTOR

Nielsen BioSciences, Inc.

Locations

Johnson Dermatology

Fort Smith, Arkansas, United States

Northwest Arkansas Clinical Trials Center PLLC

Rogers, Arkansas, United States

California Dermatology and Clinical Research Institute

Encinitas, California, United States

Silverberg MD Inc.

Newport Beach, California, United States

Metro Boston Clinical Partners, LLC

Needham, Massachusetts, United States

BayState Clinical Trials

Watertown, Massachusetts, United States

Hamzavi Dermatology Clinical Trials

Fort Gratiot, Michigan, United States

Minnesota Clinical Study Center

Fridley, Minnesota, United States

Dermatology Consulting Services

High Point, North Carolina, United States

Oregon Medical Research Center

Portland, Oregon, United States

Austin Institute for Clinical Research Inc.

Austin, Texas, United States

DermResearch Inc.

Austin, Texas, United States

Texas Dermatology and Laser Specialists

San Antonio, Texas, United States

Dermatology Research Center, Inc.

Salt Lake City, Utah, United States

The Education and Research Foundation, Inc.

Lynchburg, Virginia, United States

Countries

United States

References

Kim KH, Horn TD, Pharis J, Kincannon J, Jones R, O'Bryan K, Myers J, Nakagawa M. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol. 2010 Dec;146(12):1431-3. doi: 10.1001/archdermatol.2010.350. No abstract available.

Reference Type: RESULT

PMID: 21173332 (View on PubMed)

Smith SR, Esch RE, Nielsen HS, Johnson SM. Randomized Phase IIa Trial of Purified Candida Antigen for Common Warts: Evaluating the Safety and Efficacy Across Multiple Dosing Regimens. Dermatol Ther (Heidelb). 2025 May;15(5):1135-1152. doi: 10.1007/s13555-025-01387-1. Epub 2025 Mar 29.

Reference Type: DERIVED

PMID: 40155509 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

CFW-2D

Identifier Type: -

Identifier Source: org_study_id